Synergistic cytotoxic effect of genistein and doxorubicin on drug-resistant human breast cancer MCF-7/Adr cells

被引:60
作者
Xue, Jia-Peng [1 ]
Wang, Geng [1 ]
Zhao, Zong-Bin [1 ]
Wang, Qun [1 ]
Shi, Yun [1 ]
机构
[1] Taihe Hosp, Hubei Med Coll, Dept Endocrine & Vasc Surg, Shiyan 442000, Hubei, Peoples R China
关键词
genistein; MCF-7/Adr; reversal of multidrug resistance; doxorubicin; P-GLYCOPROTEIN; SOY ISOFLAVONE; CHEMOTHERAPY; APOPTOSIS; INHIBITION; EXPRESSION; DAIDZEIN; LOCATION; RECEPTOR; GROWTH;
D O I
10.3892/or.2014.3365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular mechanisms underlying genistein-mediated reversal of chemoresistance remains unknown. In the present study, we investigated the molecular mechanisms by which genistein overcomes chemoresistance and its effect on doxorubicin-induced cytotoxicity. Consistent with previous reports, genistein combined with doxorubicin had a synergistic effect on MCF-7/Adr cells, and genistein reduced the chemoresistance of these cells. Genistein treatment increased the intracellular accumulation of doxorubicin but did not influence P-gp function. The combination of genistein and doxorubicin significantly induced cell cycle arrest and apoptosis. Genistein treatment strongly inhibited HER2/neu but not MDR-1 expression at both the mRNA and protein levels. Therefore, our results demonstrated that genistein combined with doxorubicin had a synergistic effect on MCF-7/Adr cells, and the mechanisms likely involve an increase in the intracellular accumulation of doxorubicin and suppression of HER2/neu expression.
引用
收藏
页码:1647 / 1653
页数:7
相关论文
共 42 条
  • [1] Multi-targeted therapy of cancer by genistein
    Banerjee, Sanjeev
    Li, Yiwei
    Wang, Zhiwei
    Sarkar, Fazlul H.
    [J]. CANCER LETTERS, 2008, 269 (02) : 226 - 242
  • [2] Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial
    Bartlett, J.
    Canney, P.
    Campbell, A.
    Cameron, D.
    Donovan, J.
    Dunn, J.
    Earl, H.
    Francis, A.
    Hall, P.
    Harmer, V.
    Higgins, H.
    Hillier, L.
    Hulme, C.
    Hughes-Davies, L.
    Makris, A.
    Morgan, A.
    McCabe, C.
    Pinder, S.
    Poole, C.
    Rea, D.
    Stallard, N.
    Stein, R.
    [J]. CLINICAL ONCOLOGY, 2013, 25 (02) : 109 - 116
  • [3] Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
    Brunello, Antonella
    Roma, Anna
    Falci, Cristina
    Basso, Umberto
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2008, 3 (03) : 187 - 201
  • [4] Antiproliferative activity of daidzein and genistein may be related to ERα/c-erbB-2 expression in human breast cancer cells
    Choi, Eun Jeong
    Kim, Gun-Hee
    [J]. MOLECULAR MEDICINE REPORTS, 2013, 7 (03) : 781 - 784
  • [5] TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE
    COUSSENS, L
    YANGFENG, TL
    LIAO, YC
    CHEN, E
    GRAY, A
    MCGRATH, J
    SEEBURG, PH
    LIBERMANN, TA
    SCHLESSINGER, J
    FRANCKE, U
    LEVINSON, A
    ULLRICH, A
    [J]. SCIENCE, 1985, 230 (4730) : 1132 - 1139
  • [6] de Lemos ML, 2001, ANN PHARMACOTHER, V35, P1118, DOI 10.1345/aph.10257
  • [7] BREAST CANCER AFTER TREATMENT OF HODGKIN'S LYMPHOMA: GENERAL REVIEW
    El-Din, Mohamed A. Alm
    El-Badawy, Samy A.
    Taghian, Alphonse G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (05): : 1291 - 1297
  • [8] Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy
    Fuksa, L.
    Micuda, S.
    Grim, J.
    Ryska, A.
    Hornychova, H.
    [J]. CANCER INVESTIGATION, 2012, 30 (09) : 663 - 678
  • [9] Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
    Gampenrieder, Simon P.
    Rinnerthaler, Gabriel
    Greil, Richard
    [J]. JOURNAL OF ONCOLOGY, 2013, 2013
  • [10] GIAI M, 1991, European Journal of Gynaecological Oncology, V12, P359